ANAB vs. CVAC, COGT, GHRS, CALT, WVE, NUVB, SAGE, PHAR, MLYS, and LYEL
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include CureVac (CVAC), Cogent Biosciences (COGT), GH Research (GHRS), Calliditas Therapeutics AB (publ) (CALT), Wave Life Sciences (WVE), Nuvation Bio (NUVB), Sage Therapeutics (SAGE), Pharming Group (PHAR), Mineralys Therapeutics (MLYS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry.
AnaptysBio (NASDAQ:ANAB) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
17.3% of CureVac shares are held by institutional investors. 33.7% of AnaptysBio shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
AnaptysBio received 329 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 65.61% of users gave AnaptysBio an outperform vote while only 51.16% of users gave CureVac an outperform vote.
AnaptysBio presently has a consensus price target of $46.38, suggesting a potential upside of 84.98%. CureVac has a consensus price target of $8.33, suggesting a potential upside of 138.78%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than AnaptysBio.
In the previous week, AnaptysBio had 3 more articles in the media than CureVac. MarketBeat recorded 5 mentions for AnaptysBio and 2 mentions for CureVac. AnaptysBio's average media sentiment score of 1.22 beat CureVac's score of 0.82 indicating that AnaptysBio is being referred to more favorably in the media.
AnaptysBio has a beta of -0.32, suggesting that its stock price is 132% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500.
CureVac has a net margin of -483.85% compared to AnaptysBio's net margin of -711.17%. CureVac's return on equity of -41.87% beat AnaptysBio's return on equity.
AnaptysBio has higher earnings, but lower revenue than CureVac. AnaptysBio is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Summary
AnaptysBio and CureVac tied by winning 9 of the 18 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AnaptysBio Competitors List
Related Companies and Tools
